Evidence map›Paper›PMID 30783794›Full record

Trial reportNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2019

Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac, and chlorpromazine for pain relief and prevention of recurrence in the migraine headache: a prospective double-blind randomized clinical trial.

Mojtaba Khazaei, Nahid Hosseini Nejad Mir, Fateme Yadranji Aghdam, Mohammad Taheri, Soudeh Ghafouri-Fard

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. ED and Inpatient Management of Headache in Children and Adolescents.Current neurology and neuroscience reports · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mojtaba KhazaeiDepartment of Neurology, Hamadan University of Medical Sciences, Hamadan, Iran.
Nahid Hosseini Nejad MirDepartment of Neurology, Hamadan University of Medical Sciences, Hamadan, Iran.
Fateme Yadranji AghdamHamadan University of Medical Sciences, Hamadan, Iran.
Mohammad TaheriUrogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mohammad_823@yahoo.com.
Soudeh Ghafouri-FardDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.ghafourifard@sbmu.ac.ir.ORCID http://orcid.org/0000-0002-0223-499X
Hamedan University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

Hamadan University of Medical Sciences 5611
6 · The paper itself

Abstract

Dexamethasone, metoclopramide, ketorolac, and chlorpromazine have been used for the treatment of migraine headache. However, the effectiveness of these drugs in pain relief and prevention of recurrence and their side effects have not been compared yet. This was a randomized, double-blind clinical trial. Subjects were randomized to four groups; each received one of the following drugs intravenously: dexamethasone 8 mg, ketorolac 30 mg, metoclopramide 10 mg, and chlorpromazine 25 mg. The severity of headache in the two groups was assessed at starting point, 1 h and 24 h after the administration of drug using the visual analogue scale (VAS) on a scale of 0 to 10. No significant difference was found in the severity of symptoms between the four study groups before treatment, 1 h, and 24 h after treatment. The effect of all mentioned drugs on acute migraine headache was statistically significant at 1 and 24 h post-treatment compared to baseline. No significant difference was detected in the number of unresponsive cases between the four groups. There was a trend toward higher effectiveness of dexamethasone in prevention of recurrence (P = 0.05). Side effects were more common in chlorpromazine and less common in the dexamethasone-treated patients (P < 0.001). The present clinical trial shows the effectiveness of dexamethasone in prevention of recurrence and low frequency of treatment side effects.

Indexed as

Administration, IntravenousAdultAnalgesicsChlorpromazineDexamethasoneDouble-Blind MethodFemaleHumansKetorolacMaleMetoclopramideMigraine DisordersProspective StudiesSecondary PreventionTreatment OutcomeAnalgesicsChlorpromazineDexamethasoneKetorolacMetoclopramideChlorpromazineDexamethasoneKetorolacMetoclopramideMigraine

Identifiers

PMID30783794
OpenAlexW2915303763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.